Comera Life Sciences Holdings, Inc. (CMRA)
USD 0.0
(-50.0%)
USD 0.0
(-50.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 12.39 Million USD | 117.63% |
| 2021 | 5.69 Million USD | 130.92% |
| 2020 | 2.46 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q1 | 2.77 Million USD | -10.85% |
| 2023 Q3 | 2.25 Million USD | 29.45% |
| 2023 Q2 | 1.73 Million USD | -37.37% |
| 2022 Q3 | 2.7 Million USD | -33.35% |
| 2022 Q2 | 4.06 Million USD | 62.38% |
| 2022 Q1 | 2.5 Million USD | 21.62% |
| 2022 FY | 12.39 Million USD | 117.63% |
| 2022 Q4 | 3.11 Million USD | 14.97% |
| 2021 Q4 | 2.05 Million USD | 115.98% |
| 2021 Q3 | 953.1 Thousand USD | -50.29% |
| 2021 Q2 | 1.91 Million USD | 216.95% |
| 2021 Q1 | 604.88 Thousand USD | 0.0% |
| 2021 FY | 5.69 Million USD | 130.92% |
| 2020 FY | 2.46 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -1774.187% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -33.715% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | 58.681% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 81.544% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | 21.778% |
| Better Therapeutics, Inc. | 38.26 Million USD | 67.611% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 69.543% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 63.383% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 63.995% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 88.575% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | -1148.249% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | 61.973% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 73.605% |
| Innovation1 Biotech Inc. | 1.21 Million USD | -920.24% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | 37.848% |
| Molecular Templates, Inc. | 63.09 Million USD | 80.357% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | 11.046% |
| NexImmune, Inc. | 28.16 Million USD | 56.003% |
| Orgenesis Inc. | 45.75 Million USD | 72.916% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | 51.68% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -16780.145% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | 23.242% |
| Scopus BioPharma Inc. | 11.71 Million USD | -5.786% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 96.929% |
| Statera Biopharma, Inc. | 28.82 Million USD | 57.014% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | 34.53% |
| Trevena, Inc. | 38.41 Million USD | 67.738% |
| Vaxxinity, Inc. | 56.05 Million USD | 77.89% |
| Vaccinex, Inc. | 23.45 Million USD | 47.164% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | -1083.666% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 75.553% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -70.356% |